Amgen (NASDAQ:AMGN) and Takeda Pharmaceutical said on Wednesday that their experimental cancer drug failed to improve overall survival in patients with advanced lung cancer.
The late-stage study of the drug, called motesanib, in 1,090 patients with non-squamous non-small cell lung cancer did not meet its objective.
Continue Reading Below
“We are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area,” said Dr. Roger Perlmutter, executive vice president of research and development at Amgen.
Amgen said the adverse events for the investigational medication were consistent with that seen in previous studies.